Comparative Efficacy and Safety of Different Orforglipron Doses in Patients With Type 2 Diabetes Mellitus and Obesity: A Systematic Review and Network Meta-Analysis.
Orforglipron may lead to meaningful reductions in BMI and HbA1c, particularly at higher doses, but comes with increased rates of adverse events and treatment discontinuation.
Where it sits
this study against the rest of the orforglipron (ly-3502970) corpusSummary and findings
This systematic review and network meta-analysis evaluated the efficacy and safety of various doses of orforglipron in patients with type 2 diabetes mellitus and obesity. The study included five randomized controlled trials (RCTs) with doses ranging from 3 to 45 mg. Higher doses, particularly 45 mg, were associated with reductions in body weight and glycemic control metrics.
Abstract
Type 2 diabetes mellitus (T2DM) and obesity represent major global health challenges. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have emerged as effective treatments for both conditions, providing significant glycemic control and weight-reduction benefits. Orforglipron is an investigational, oral, non-peptide GLP-1RA that does not require complex absorption enhancers or dosing restrictions. Preclinical and early clinical studies have demonstrated promising results in glycemic control and weight reduction. This systematic review and network meta-analysis aims to evaluate the efficacy and safety of various orforglipron doses in improving glycemic control and reducing body weight. We conducted a search across five databases. A frequentist network meta-analysis with random-effects models was performed using MetaInsight (version 3.14) to analyze randomized controlled trials(RCTs) comparing orforglipron with placebo in patients with obesity or diabetes. Efficacy outcomes (HbA1c, body weight, BMI, lipid profile, blood pressure) were reported as mean differences, and safety outcomes (adverse events) as risk ratios, with 95% CIs. Five RCTs involving multiple orforglipron doses (3-45 mg) demonstrated that higher doses, particularly 45 mg, significantly reduced BMI (MD = -3.52 kg/m²), body weight (MD = -9.34%), waist circumference (MD = -7.19 cm), HbA1c (MD = -1.33%), triglycerides (MD = -15.31% for 36 mg), and blood pressure compared to placebo. All doses showed higher rates of total adverse events and treatment discontinuation than placebo, while serious adverse events and specific gastrointestinal symptoms (nausea, vomiting, dyspepsia) were lower than placebo. Orforglipron is particularly suitable for patients preferring oral therapy over injectable GLP-1 receptor agonists. Orforglipron demonstrated significant dose-dependent improvements in patients with obesity (with or without comorbidities) and T2DM, with higher doses (36-45 mg) showing greater efficacy for weight loss and glycemic control, though at the cost of increased treatment discontinuation. Mid-range doses (24-36 mg) may be better suited for patients prioritizing lipid management and blood pressure control while seeking improved tolerability with a lower discontinuation risk.
Background
The paper addresses the comparative efficacy and safety of Orforglipron, a novel peptide, in managing Type 2 Diabetes Mellitus and obesity. Prior studies have indicated potential benefits of Orforglipron, but comprehensive comparisons across different doses were lacking. This systematic review and network meta-analysis aims to fill that gap by synthesizing available evidence.
Methods
The study employed a systematic review and network meta-analysis design, including various clinical trials that assessed different doses of Orforglipron. The population consisted of patients diagnosed with Type 2 Diabetes Mellitus and obesity, but specific sample sizes and dosing regimens were not detailed in the abstract. The duration of treatment and primary versus secondary outcome measures were also not reported.
Results
Not reported in abstract.
Interpretation
Given the lack of specific numeric findings in the abstract, it is difficult to compare the results to existing literature or assess the clinical significance of the findings. The absence of detailed data limits the ability to draw firm conclusions regarding the efficacy and safety of Orforglipron at different doses. Potential confounding factors such as study design and population characteristics may also affect the reliability of the conclusions.
Key findings
- Not reported in abstract.
Limitations
- Not reported in abstract.